vs
Side-by-side financial comparison of Baxter International (BAX) and SOMNIGROUP INTERNATIONAL INC. (SGI). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $1.9B, roughly 1.6× SOMNIGROUP INTERNATIONAL INC.). SOMNIGROUP INTERNATIONAL INC. runs the higher net margin — 7.5% vs -37.9%, a 45.5% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 54.7%). Over the past eight quarters, SOMNIGROUP INTERNATIONAL INC.'s revenue compounded faster (25.3% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Somnigroup International Inc. is an American manufacturer of mattresses and bedding products.
BAX vs SGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $1.9B |
| Net Profit | $-1.1B | $140.8M |
| Gross Margin | 19.4% | 44.0% |
| Operating Margin | -24.5% | 13.2% |
| Net Margin | -37.9% | 7.5% |
| Revenue YoY | 458.0% | 54.7% |
| Net Profit YoY | -120.3% | 95.8% |
| EPS (diluted) | $-2.21 | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $1.9B | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $2.8B | $1.9B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $533.0M | $1.2B | ||
| Q3 24 | $2.7B | $1.3B | ||
| Q2 24 | $3.8B | $1.2B | ||
| Q1 24 | $3.6B | $1.2B |
| Q4 25 | $-1.1B | $140.8M | ||
| Q3 25 | $-46.0M | $177.4M | ||
| Q2 25 | $91.0M | $99.0M | ||
| Q1 25 | $126.0M | $-33.1M | ||
| Q4 24 | $-512.0M | $71.9M | ||
| Q3 24 | $140.0M | $130.0M | ||
| Q2 24 | $-314.0M | $106.1M | ||
| Q1 24 | $37.0M | $76.3M |
| Q4 25 | 19.4% | 44.0% | ||
| Q3 25 | 33.5% | 44.9% | ||
| Q2 25 | 35.3% | 44.0% | ||
| Q1 25 | 32.8% | 36.2% | ||
| Q4 24 | 25.0% | 43.3% | ||
| Q3 24 | 38.3% | 45.4% | ||
| Q2 24 | 37.5% | 44.9% | ||
| Q1 24 | 38.6% | 43.1% |
| Q4 25 | -24.5% | 13.2% | ||
| Q3 25 | 6.1% | 14.8% | ||
| Q2 25 | 6.8% | 9.6% | ||
| Q1 25 | 2.2% | 0.8% | ||
| Q4 24 | -25.5% | 10.6% | ||
| Q3 24 | 5.7% | 15.5% | ||
| Q2 24 | -5.0% | 14.0% | ||
| Q1 24 | 5.2% | 11.1% |
| Q4 25 | -37.9% | 7.5% | ||
| Q3 25 | -1.6% | 8.4% | ||
| Q2 25 | 3.2% | 5.3% | ||
| Q1 25 | 4.8% | -2.1% | ||
| Q4 24 | -96.1% | 6.0% | ||
| Q3 24 | 5.2% | 10.0% | ||
| Q2 24 | -8.2% | 8.6% | ||
| Q1 24 | 1.0% | 6.4% |
| Q4 25 | $-2.21 | $0.71 | ||
| Q3 25 | $-0.09 | $0.83 | ||
| Q2 25 | $0.18 | $0.47 | ||
| Q1 25 | $0.25 | $-0.17 | ||
| Q4 24 | $-0.99 | $0.40 | ||
| Q3 24 | $0.27 | $0.73 | ||
| Q2 24 | $-0.62 | $0.60 | ||
| Q1 24 | $0.07 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | — |
| Total DebtLower is stronger | $9.5B | $4.6B |
| Stockholders' EquityBook value | $6.1B | $3.1B |
| Total Assets | $20.1B | $11.6B |
| Debt / EquityLower = less leverage | 1.55× | 1.47× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $9.5B | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $4.9B | ||
| Q4 24 | $10.4B | $3.7B | ||
| Q3 24 | $10.4B | $2.2B | ||
| Q2 24 | $10.4B | $2.4B | ||
| Q1 24 | $11.1B | $2.5B |
| Q4 25 | $6.1B | $3.1B | ||
| Q3 25 | $7.2B | $3.0B | ||
| Q2 25 | $7.3B | $2.8B | ||
| Q1 25 | $7.1B | $2.7B | ||
| Q4 24 | $7.0B | $559.0M | ||
| Q3 24 | $7.9B | $564.5M | ||
| Q2 24 | $7.6B | $411.8M | ||
| Q1 24 | $8.2B | $326.6M |
| Q4 25 | $20.1B | $11.6B | ||
| Q3 25 | $21.1B | $11.4B | ||
| Q2 25 | $21.0B | $11.4B | ||
| Q1 25 | $21.3B | $11.3B | ||
| Q4 24 | $25.8B | $6.0B | ||
| Q3 24 | $26.7B | $4.6B | ||
| Q2 24 | $26.3B | $4.6B | ||
| Q1 24 | $27.8B | $4.6B |
| Q4 25 | 1.55× | 1.47× | ||
| Q3 25 | — | 1.51× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | 1.49× | 6.69× | ||
| Q3 24 | 1.33× | 3.95× | ||
| Q2 24 | 1.37× | 5.92× | ||
| Q1 24 | 1.36× | 7.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $99.4M |
| Free Cash FlowOCF − Capex | — | $41.1M |
| FCF MarginFCF / Revenue | — | 2.2% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | 0.71× |
| TTM Free Cash FlowTrailing 4 quarters | — | $633.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $99.4M | ||
| Q3 25 | $237.0M | $408.2M | ||
| Q2 25 | $217.0M | $186.1M | ||
| Q1 25 | $-193.0M | $106.4M | ||
| Q4 24 | $488.0M | $129.1M | ||
| Q3 24 | $253.0M | $256.6M | ||
| Q2 24 | $115.0M | $150.6M | ||
| Q1 24 | $163.0M | $130.2M |
| Q4 25 | — | $41.1M | ||
| Q3 25 | — | $360.3M | ||
| Q2 25 | — | $149.4M | ||
| Q1 25 | — | $82.4M | ||
| Q4 24 | — | $108.2M | ||
| Q3 24 | — | $240.2M | ||
| Q2 24 | — | $122.1M | ||
| Q1 24 | — | $98.7M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 7.9% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 9.9% | ||
| Q1 24 | — | 8.3% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 2.30× | ||
| Q2 25 | 2.38× | 1.88× | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | 1.80× | ||
| Q3 24 | 1.81× | 1.97× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | 4.41× | 1.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
SGI
| Mattress Firm Segment | $892.1M | 48% |
| Tempur Sealy North America Segment | $620.5M | 33% |
| Tempur Sealy International Segment | $355.8M | 19% |
